GeoVax Labs Inc GOVX.OQ GOVX.O is expected to show a fall in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for GeoVax Labs Inc is for a loss of 26 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for GeoVax Labs Inc is $9.00, about 94.2% above its last closing price of $0.52
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.39 | -0.36 | -0.35 | Beat | 2.8 |
Mar. 31 2025 | -0.57 | -0.67 | -0.45 | Beat | 32.5 |
Dec. 31 2024 | -0.77 | -0.30 | Beat | 60.9 | |
Sep. 30 2024 | -1.43 | -1.48 | -0.91 | Beat | 38.4 |
Jun. 30 2024 | -2.51 | -3.36 | -1.99 | Beat | 40.9 |
Mar. 31 2024 | -5.56 | -5.56 | -2.47 | Beat | 55.6 |
Dec. 31 2023 | -2.27 | -2.78 | -13.60 | Missed | -389.8 |
Sep. 30 2023 | -3.60 | -3.60 | -4.80 | Missed | -33.3 |
This summary was machine generated November 7 at 22:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)